Johnson & Johnson (JNJ)
| Market Cap | 432.91B |
| Revenue (ttm) | 80.86B |
| Net Income (ttm) | 16.99B |
| Shares Out | 2.63B |
| EPS (ttm) | 6.36 |
| PE Ratio | 25.72 |
| Forward PE | 17.73 |
| Dividend | $4.04 |
| Dividend Yield | 2.47% |
| Trading Day | January 22 |
| Last Price | $163.55 |
| Previous Close | $161.73 |
| Change ($) | 1.82 |
| Change (%) | 1.13% |
| Day's Open | 162.25 |
| Day's Range | 161.87 - 165.16 |
| Day's Volume | 8,137,018 |
| 52-Week Range | 108.89 - 165.16 |
Moderna and Pfizer/BioNTech should rake in similar levels of revenue for their vaccines.
Final Trades: Apple, IBM, Johnson & Johnson & more
The "Halftime Report" traders give their top picks to watch for the second half.
Regional Banks Post Mixed Earnings Results.
J&J's (JNJ) Pharma segment is expected to have performed above market while continued procedure stabilization is expected to have benefited the Medical Devices segment in the fourth quarter.
Johnson & Johnson hopes to have enough COVID-19 vaccines for 100 million Americans by April as the feds ramp up nationwide inoculation efforts, a company official says.
Less may be more when it comes to rolling out a coronavirus vaccine. Johnson & Johnson's one-dose vaccine could have an edge over Pfizer and Moderna's shots– even though it's still several wee...
Bloomberg reports that Johnson & Johnson (NYSE: JNJ) is on track to analyze data from its late-stage single-dose COVID-19 vaccine trial. Dr. Anthony Fauci said in his remarks at the White Hous...
The lowest yield on this list is 2.5% and well above what the average S&P 500 stock pays today.
2020, for our investments, was a good year. We kept the cash from the Emera sale for emergency funds during the first lockdown when we weren't working.
A J&J board member said “if the clinical trial works out,” the company could significantly increase the nation's Covid vaccine supply availability.
Starting 2021 by looking at the Long Ideas that performed poorly in 2020. Despite their underperformance, we remain bullish on these stocks, and they all remain open long ideas.
Take a look at a few trending biotech stocks and decide if this is something you want to invest in.
This innovative drugmaker is expecting multiple growth catalysts in 2021.
These stocks won't keep you up at night.
Healthcare aristocrats benefit from significant medical device contributions. By and large these healthcare aristocrats share favorable quant metrics on Seeking Alpha, albeit with significant ...
Don't let an expensive share price stop you from buying the best.
In the latest trading session, Johnson & Johnson (JNJ) closed at $162.38, marking a -0.25% move from the previous day.
Covid-19 pharma stocks like NVAX stock and BNTX stock are making headlines as Joe Biden promises to vaccinate 100 million Americans. The post Covid-19 Vaccine Roundup: 5 Pharma Stocks Making t...
If you have a long-term outlook for your portfolio, these beginner stocks to buy should make you very happy down the line. The post 9 Beginner Stocks for First-Time Investors appeared first on...
In December, we received $4,699.20 in dividend income. That is a 23.4% increase compared to last year. We received $3,500 from our retirement accounts this month alone. In total, our dividend ...
The Dow Jones Industrial Index is one of the cornerstone indexes of the U.S. markets. But it's more consumer-driven now.
Nearby levels of support and recent closes beyond key resistance are creating lucrative risk/reward setups in the healthcare sector.
Starting 2021 by looking at the Long Ideas that performed poorly in 2020 that I remain bullish on.
Johnson & Johnson is developing one of the most closely watched Covid-19 vaccines, considering that it is a single-dose shot that should be relatively easy to distribute. Here's a quick rundow...
You can just sit back and watch the cash roll in with these two top stocks.
J&J (JNJ) gets accelerated approval for a new indication of Darzalex Faspro in combination with bortezomib, cyclophosphamide and dexamethasone for treating amyloidosis patients.
The possibility of a one-dose vaccine may give it an edge over rivals.
Week 3 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An Edge
Each has more to offer than just a COVID-19 vaccine.
Holding on to stocks for the long haul is a good way to build wealth -- as long as you've picked strong and growing enterprises. Here are three to consider.
New strains of virus discovered in the U.S., J&J vaccine generates immune response
Former FDA Commissioner Dr. Scott Gottlieb discusses news that two new Covid strains have been discovered in the U.S. by researchers at Ohio State University.
Johnson & Johnson (JNJ) closed the most recent trading day at $160.65, moving +1.75% from the previous trading session.
J&J lab data is encouraging, need human trial data: Ex-CDC director
CNBC's "Closing Bell" team discusses Johnson & Johnson's latest data on its Covid vaccine and rollout in the U.S., with Dr. Tom Frieden, former CDC director.
Those are some solid endorsements.
Johnson & Johnson one dose vaccine sees immune response in early trials
Dr. Uche Blackstock, CEO of Advancing Health Equity and Yahoo News Medical Contributor weighs in on the Johnson & Johnson vaccine and the need to for the public to continue to follow measures ...
Year 2020 was wild, and left many important threats for 2021. I will summarize the key threats I see, and offer my approach to the markets.
Johnson & Johnson one shot coronavirus vaccine is safe
Participants in the COVID-19 vaccine trials at Johnson & Johnson produced a positive immune response. Subscribe to Fox Business!
Johnson & Johnson's coronavirus vaccine generated a lasting immune response to the deadly bug in an early-stage clinical trial, the pharmaceutical giant said.
Shares of Johnson & Johnson gained 1.7% in premarket trading on Thursday, the day after a study published in the New England Journal of Medicine showed that its COVID-19 vaccine candidate gene...
J&J reports positive phase 1/2 Covid vaccine trial results
CNBC's Meg Tirrell reports that Johnson & Johnson has seen positive results from its Covid vaccine trial. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Pete Najar...
The new clinical trial data shows a single shot of the vaccine "gives sustainable antibodies," Dr. Paul Stoffels, J&J chief scientific officer, told CNBC.
Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.
Johnson & Johnson said it's premature to discuss the details of its coronavirus vaccine supply after JNJ stock slipped Wednesday on a report it's two months behind schedule. The post J&J Stock...
These stocks are as solid as they come.
Johnson & Johnson is facing unexpected delays in the manufacturing of its coronavirus vaccine and may not be able to supply the doses it promised the federal government by spring, the New York...
Federal officials have been told that Johnson & Johnson's vaccine production has fallen as much as two months behind the original production schedule and won't catch up until the end of April,...
Johnson & Johnson (JNJ) closed at $158.13 in the latest trading session, marking a -0.78% move from the prior day.
With solid valuations and good dividends, these businesses will get you through the next rainy day -- or year.
In this new series, I am hoping folks realize that the stocks I'm suggesting could provide an income for life, so you don't go broke before you kick the bucket. Obviously these should be a por...
About JNJ
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; ... [Read more...]
| Industry Drug Manufacturers-General | Founded 1886 |
| CEO Alex Gorsky | Employees 132,200 |
| Stock Exchange NYSE | Ticker Symbol JNJ |
Financial Performance
In 2019, JNJ's revenue was $82.06 billion, an increase of 0.59% compared to the previous year's $81.58 billion. Earnings were $15.12 billion, a decrease of -1.16%.
Analyst Forecasts
According to 19 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is 168.18, which is an increase of 2.83% from the latest price.